news
Lack of gender equality in COVID-19 decision-making could be costing lives
New research suggests male predominance in COVID-19 expert groups and task forces is undermining the pandemic response.
List view / Grid view
Regulation & Legislation
news
Failure to secure ‘bare minimum’ deal on medicines could put patients at risk, MPs told
1 October 2020 | By
UK politicians were warned that without a post-Brexit deal on medicines, short-term supply delays could be damaging to both public health and the economy.
article
Return to work for life sciences: an evolving challenge
Helen Farr, a Partner at Taylor Wessing, discusses the hurdles that life science businesses must tackle to bring employees back to work safely; whether that be working remotely or returning to the lab.
news
UK to create the most advanced genomic healthcare system in the world
The UK’s Health and Social Secretary has launched a new healthcare strategy based on harnessing the potential of advanced genome sequencing for both research and clinical purposes.
news
UK and EU pharma call for medicines to be prioritised in Brexit trade talks
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
news
Global anti-counterfeit packaging market to grow to $17.47 billion
Growth in the anti-counterfeit technologies market will be particularly large in the pharma industry due to increasing awareness around health and safety, says report.
news
Herd immunity is an impractical COVID-19 mitigation strategy, says study
Researchers who designed a transmission model for COVID-19 demonstrated that attempting to establish herd immunity against COVID-19 would be too challenging.
news
EMA recommends seven medicines for approval after September meeting
Following its latest meeting, the EMA's CHMP has suggested granting marketing authorisation to seven medicines and extending the indications of 15 others.
article
Post-Brexit product supply: which way next for pharma?
Cecilia Avram details the requirements for pharma companies post-Brexit and provides practical pointers on minimising the disruption to cross-border product availability as new rules come into force.
news
Alter Pharma Group adopts Movilitas.Cloud to ensure safer goods and EU FMD compliance
Movilitas has announced that Alter Pharma Group has adopted its Movilitas.Cloud software to meet requirements throughout the product path and changes in packaging under the EU FMD regulation.
news
UK government inks deal for 60 million doses of Valneva COVID-19 vaccine
Valneva has agreed to supply the UK government with 60 million doses of its potential COVID-19 vaccine by the second half of 2021.
news
Promising interim results from ALS study testing IPL344
The data suggests disease deterioration was halved in the six Amyotrophic Lateral Sclerosis (ALS) patients treated with IPL344 over eight months.
news
British pharma responds to free trade agreement between UK and Japan
The ABPI has said that the new UK-Japan free trade agreement will benefit the pharma industry, providing continuity for life science businesses.
news
Imfinzi approved in EU to treat extensive-stage small cell lung cancer
Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.
news
Russia to supply Mexico with 32 million doses of Sputnik V
The Russian Direct Investment Fund (RDIF) said the supply of the COVID-19 vaccine should enable 25 percent of the population to be vaccinated.
